ZGBEF yields 0.28% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, ZGBEF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ZGBEF + JNJ for your $10,000?
2G Energy AG, together with its subsidiaries, develops, manufactures, and installs combined heat and power (CHP) systems, and other systems for the recovery of electrical energy in Germany and internationally. It offers decentralized power and heat through gas motors driven by natural gas, biomethane, biogas, sewage gas, landfill gas, or hydrogen with an electrical output of 20 to 4,500 kW. The company's products include g-box, a natural gas CHP plant with the electrical output of 20 kW to 50 kW; aura, a CHP plant with the output range from 100 kW to 420 kW; patruus, a biogas and natural gas CHP plant with the output range from 50 kW to 263 kW; agenitor, a CHP plant with a capacity of 220 kW to 450 kW; and avus, a CHP plant with the electrical output range of 400 kW to 4.000 kW. It also engages in the rental and leasing of CHP plants. The company's products are used for various applications, such as biogas plants, office and administrative buildings, chemical and pharmaceutical industries, landfills, shopping centers, horticultural and agricultural holdings, hotels, industry and trade, sewage treatment plants, hospitals, food industry, public institutions, data processing centers, schools and universities, swimming pools, senior citizen centers, sports and leisure centers, heat grids, hydrogen, and residential buildings. The company was formerly known as 2G Bio-Energietechnik AG and changed its name to 2G Energy AG in 2011. 2G Energy AG was founded in 1995 and is headquartered in Heek, Germany.
Full ZGBEF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.